scholarly journals Anti-Allergic Potential of Cinnamaldehyde via the Inhibitory Effect of Histidine Decarboxylase (HDC) Producing Klebsiella pneumonia

Molecules ◽  
2020 ◽  
Vol 25 (23) ◽  
pp. 5580
Author(s):  
Lorina I. Badger-Emeka ◽  
Promise Madu Emeka ◽  
Krishnaraj Thirugnanasambantham ◽  
Hairul Islam M. Ibrahim

Allergy is an immunological disorder that develops in response to exposure to an allergen, and histamines mediate these effects via histidine decarboxylase (HDC) activity at the intracellular level. In the present study, we developed a 3D model of Klebsiella pneumoniae histidine decarboxylase (HDC) and analyzed the HDC inhibitory potential of cinnamaldehyde (CA) and subsequent anti-allergic potential using a bacterial and mammalian mast cell model. A computational and in vitro study using K. pneumonia revealed that CA binds to HDC nearby the pyridoxal-5′-phosphate (PLP) binding site and inhibited histamine synthesis in a bacterial model. Further study using a mammalian mast cell model also showed that CA decreased the levels of histamine in the stimulated RBL-2H3 cell line and attenuated the release of β-hexoseaminidase and cell degranulation. In addition, CA treatment also significantly suppressed the levels of pro-inflammatory cytokines TNF-α and IL-6 and the nitric oxide (NO) level in the stimulated mast cells. A gene expression and Western blotting study revealed that CA significantly downregulated the expressions of MAPKp38/ERK and its downstream pro-allergic mediators that are involved in the signaling pathway in mast cell cytokine synthesis. This study further confirms that CA has the potential to attenuate mast cell activation by inhibiting HDC and modifying the process of allergic disorders.

2020 ◽  
Vol 41 (4) ◽  
pp. 778-816
Author(s):  
Muhammad Novrizal Abdi Sahid ◽  
Takeshi Kiyoi

Neuropeptides ◽  
2019 ◽  
Vol 74 ◽  
pp. 52-59 ◽  
Author(s):  
Scott P. Levick ◽  
Gregory L. Brower ◽  
Joseph S. Janicki

1994 ◽  
Vol 257 (1-2) ◽  
pp. 87-93 ◽  
Author(s):  
Cleria M.M. Giraldelo ◽  
Aldete Zappellini ◽  
Marcelo N. Muscará ◽  
Iara M.S. De Luca ◽  
Stephen Hyslop ◽  
...  

1999 ◽  
Vol 106 (1) ◽  
pp. 208-215 ◽  
Author(s):  
Gardiner ◽  
Harrison ◽  
Chavda ◽  
Mackie ◽  
Machin

2001 ◽  
Vol 194 (2) ◽  
pp. 227-234 ◽  
Author(s):  
Massoud Daheshia ◽  
Daniel S. Friend ◽  
Michael J. Grusby ◽  
K. Frank Austen ◽  
Howard R. Katz

gp49B1 is an immunoglobulin (Ig) superfamily member that inhibits FcεRI-induced mast cell activation when the two receptors are coligated with antibodies in vitro. The critical question of in vivo function of gp49B1 is now addressed in gene-disrupted mice. gp49B1-deficient mice exhibited a significantly increased sensitivity to IgE-dependent passive cutaneous anaphylaxis as assessed by greater tissue swelling and mast cell degranulation in situ. Importantly, by the same criteria, the absence of gp49B1 also resulted in a lower threshold for antigen challenge in active cutaneous anaphylaxis, in which the antigen-specific antibody levels were comparable in gp49B1-deficient and sufficient mice. Moreover, the absence of gp49B1 resulted in a significantly greater and faster death rate in active systemic anaphylaxis. These results indicate that gp49B1 innately dampens adaptive immediate hypersensitivity responses by suppressing mast cell activation in vivo. In addition, this study provides a new concept and target for regulation of allergic disease susceptibility and severity.


Sign in / Sign up

Export Citation Format

Share Document